New hope for myeloma: experimental drug combo aims to beat standard care

NCT ID NCT07247097

Not yet recruiting Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial compares two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or have deferred a stem cell transplant. One group gets the experimental drug elranatamab plus standard medications (lenalidomide, bortezomib, dexamethasone), while the other gets the approved drug daratumumab with the same standard medications. The main goal is to see which combination leads to fewer cancer cells remaining after treatment. About 160 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elranatamab (a bispecific antibody) combined with lenalidomide, bortezomib, and dexamethasone
What this could lead to: If successful, this could offer a new, more effective first-line treatment option for multiple myeloma patients who cannot have a stem cell transplant.
What could go wrong: This is an early phase 2 trial with only 160 participants, so results may not apply to everyone. The new drug combination may cause side effects or not work better than the current standard.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA NEWLY DIAGNOSED MULTIPLE MYELOMA NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT INELIGIBLE

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.